| 
		Baby formula crunch in U.S. forces scramble to boost supplies
		 Send a link to a friend 
		
		 [May 20, 2022]  (Reuters) 
		- The nationwide shortage of baby formula 
		has prompted the United States to temporarily allow foreign imports from 
		other suppliers, while reaching a deal with Abbott Laboratories on steps 
		to resume production at its Michigan plant. 
 Top infant formula makers, including Reckitt Benckiser, Nestle and 
		Danone SA, are also ramping up supplies to the country.
 
 Here is a timeline of how the crisis unfolded and measures being taken 
		to resolve it:
 
 Feb. 17
 
 Abbott recalls dozens of types of powdered baby formulas, including 
		Similac, Alimentum and EleCare, made at its Sturgis, Michigan plant 
		after four consumers complained about bacterial infections in infants 
		who had consumed those products; Recalled products had an expiry date of 
		April 1, 2022 or later.
 
 Feb. 21
 
 China's custom officials warn consumers against buying and consuming 
		certain of Abbott's infant and baby products.
 
 Feb. 28
 
 Abbott expands recall to include some Similac PM 60/40 products based on 
		a fifth complaint of a bacterial infection.
 
 
		
		 
		March 4
 
 House Appropriations Committee Chairwoman Rosa DeLauro asks for an 
		investigation https://delauro.house.gov/media-center/press-releases/chair-delauro-requests-investigation-fda-handling-abbott-powdered-infant 
		into the FDA's handling of the Abbott recall.
 
 March 9
 
 The Salmonella Newport illness, which was previously included in the 
		investigation of complaints and illnesses, has been removed, the FDA 
		says. The regulator has determined that there is not enough information 
		to definitively link the illness to powdered infant formula.
 
 March 22
 
 FDA probe of Abbott's Michigan facility finds a harmful bacteria called 
		Cronobacter sakazakii on the surface of some areas near infant formula 
		production and reveals Abbott did not have a control system covering all 
		stages of processing to prevent microbe contamination.
 
 April 20
 
 Abbott cuts full-year sales growth forecast, citing the voluntary recall 
		of the infant formula products but keeps profit estimate. Abbott calls 
		the recall a "short-term hindrance".
 
 April 28
 
 House Appropriations Committee Chair Rosa DeLauro in a testimony submits 
		a report acquired from a whistleblower, who had worked at the Abbott 
		facility and had filed a complaint with the FDA in September 2021.
 
 April 29
 
 Abbott says it will release limited quantities of nutrition products 
		that were put on hold after February recall.
 
 
		
		 
		May 10
 
 Major U.S. retailers including Target Corp, CVS Health Corp, Walgreens 
		Boots Alliance and Kroger Co place purchase limits on infant formula 
		products.
 
 Abbott says it has been prioritizing production of formula at other 
		plants and ships formula from its Ireland facility.
 
 May 11
 
 U.S. lawmakers plan to hold a hearing on May 25, the House Energy and 
		Commerce Committee says, calling the shortage "increasingly alarming".
 
		
            [to top of second column] | 
            
			 
            
			Kim Anatra checks the label of a formula available at a grocery 
			store as she struggles to find formula for her 5-month-old daughter, 
			Sienna, amid continuing nationwide shortages in infant and toddler 
			formula, in Houston, Texas, U.S., May 19, 2022. REUTERS/Callaghan 
			O'Hare 
            
			 
Abbott says it could restart production at its Michigan facility within two 
weeks following approval from the FDA, but add that it would take six to eight 
weeks for the product to hit the shelves after the resumption. 
May 12
 President Joe Biden meets with executives from baby formula manufacturers and 
retailers including Target, Walmart and Nestle's Gerber to address the shortage.
 
 U.S. House Appropriations Committee says FDA Commissioner Robert Califf is set 
to testify the agency's response to the shortage before the panel on May 19.
 
 May 13
 
 The U.S. House Oversight Committee plans to investigate the shortage, saying it 
has sent letters seeking information to the four largest manufacturers of baby 
formula - Abbott Nutrition, Mead Johnson Nutrition, Nestle USA and Perrigo.
 
 U.S. Centers for Disease Control and Prevention (CDC) closes its investigation 
on Abbott, while Abbott said it has air shipped millions of cans of baby formula 
powder into the United States from its facility in Ireland.
 
 Store-brand baby formula maker Perrigo Co says shortages and heightened demand 
may last for the rest of the year.
 
 May 16
 
 The FDA says the United States will allow imports of infant formula from foreign 
makers that do not usually sell their products in the country.
 
 Abbott reaches agreement with the FDA on the steps needed to resume production 
at its Michigan plant.
 
 May 17
 
 U.S. House Democrats unveil a bill to provide $28 million in emergency funds to 
the FDA to help it respond to the shortage and bolster supervision of the 
industry.
 
 
 
Nestle SA told Reuters it was flying supplies to the country from the 
Netherlands and Switzerland. Reckitt Benckiser, the second largest U.S. milk 
formula supplier, is boosting baby formula production by about 30%.
 
 May 18
 
 U.S. President Biden invokes the Defense Production Act to help manufacturers 
obtain the ingredients needed to ramp up supply.
 
 Several Canadian retailers have imposed purchase limits on baby formula 
products, says Retail Council of Canada spokesperson, adding the country has not 
been as hard hit by the shortage.
 
 May 19
 
 Abbott and the FDA are on track to reopen the company's Michigan plant within 
one or two weeks, FDA Commissioner Robert Califf says.
 
 May 20
 
 French baby formula maker Danone SA has ramped up shipments of infant formula 
from Europe to the United States, according to U.S. customs data and shipping 
consultancy Ocean Audit.
 
 (Reporting by Deborah Sophia and Leroy Leo in Bengaluru; Editing by Anil D'Silva 
and Sriraj Kalluvila)
 
 
				 
			[© 2022 Thomson Reuters. All rights 
				reserved.]This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. 
			
			
			 |